TME PHARMA PROVIDES RESULTS OF ITS 2023 ANNUAL GENERAL MEETING OF SHAREHOLDERS AND ANNOUNCES THE RESUMPTION OF THE LIQUIDITY CONTRACT

Berlin, Germany, June 30, 2023, 06.00 p.m. CEST – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the results of its 2023 annual general meeting of shareholders (AGM), which took place on June 29, 2023, at 01:30 p.m. CEST. Shareholders representing a total of 39.86% of the total issued and outstanding share capital on June 01, 2023, were represented in person or by proxy.

All proposed resolutions submitted to the AGM were approved, as outlined below.

Following the approval of agenda item 7, and effective as of July 03, 2023, the company reinstates the liquidity contract with Invest Securities that was temporarily suspended as of March 28, 2023. As a reminder, *TME Pharma* have signed the liquidity agreement with INVEST SECURITIES on September 12, 2016. This agreement complies with the AMAFI Chart and with the decision of the French Financial Market Authority (Autorité des marchés financiers or AMF) N°2021-01 of June 22, 2021, establishing an accepted market practice in relation to liquidity contracts on shares and any other provisions referred to therein. The number of shares and cash balance allocated to the Liquidity Contract on March 28, 2023, the date of suspension, were 14,630 shares and €15,971.59.

In compliance with *TME Pharma* 2023 AGM dated June 29, 2023, the buy-back program authorized the company to acquire its own shares with a minimum price of €0.01 and a maximum price of €50.00.

Item	**Resolution**
2.c: Adoption of the annual accounts 2022	Accepted
2.d: Release from liability of the members of the board of directors	Accepted
2.e: Release from liability of the members of the supervisory board	Accepted
3: Re-appointment of Susan Coles as member of the supervisory board	Accepted
4: Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2023	Accepted
5: Partial amendment of articles of association in relation (i) to the increase of the authorized share capital and (ii) to (re-instating) a transitional provision to further increase the authorized share capital	Accepted
6: Delegation to the board of directors to issue ordinary shares and/or preference shares and to limit or exclude any pre-emptive rights in connection therewith	Accepted
7: Renewal of the delegation to the board of directors to acquire shares	Accepted

The presentation outlining the agenda items and voting results of the AGM is available online. The minutes of the AGM will soon be made available on the company website.

For more information, please contact:

TME Pharma N.V.
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 726247 0
investors@tmepharma.com

Investor and Media Relations:

LifeSci Advisors
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com

NewCap
Arthur Rouillé
Tel. +33 (0) 1 44 71 00 15
arouille@newcap.fr

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses. NOX-A12 in combination with radiotherapy has received orphan drug designation for glioblastoma in the United States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France and Spain and is in discussion with regulatory authorities in the United States. The company's second clinical-stage drug

candidate, NOX-E36, is designed to target the innate immune system. *TME Pharma* is considering several solid tumors for further clinical development. Further information can be found at: www.tmepharma.com.

TME Pharma® and the *TME Pharma* logo are registered trademarks.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit *TME Pharma* on LinkedIn and Twitter.

About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.